vs
Side-by-side financial comparison of Axe Compute Inc. (AGPU) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $8.7K, roughly 3172.6× Axe Compute Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -1740028.0%, a 1740022.1% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs -1.3%). Over the past eight quarters, Axe Compute Inc.'s revenue compounded faster (33.6% CAGR vs 21.8%).
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
AGPU vs SMTI — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $8.7K | $27.5M |
| Net Profit | $-150.9M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | -1990880.1% | 23.5% |
| Net Margin | -1740028.0% | -5.9% |
| Revenue YoY | -1.3% | 4.6% |
| Net Profit YoY | -6856.6% | 5.3% |
| EPS (diluted) | — | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.7K | $27.5M | ||
| Q3 25 | $3.6K | $26.3M | ||
| Q2 25 | $2.7K | $25.8M | ||
| Q1 25 | $110.3K | $23.4M | ||
| Q4 24 | $8.8K | $26.3M | ||
| Q3 24 | $3.9K | $21.7M | ||
| Q2 24 | $67.3K | $20.2M | ||
| Q1 24 | $4.9K | $18.5M |
| Q4 25 | $-150.9M | $-1.6M | ||
| Q3 25 | $-77.7M | $-30.4M | ||
| Q2 25 | $-2.1M | $-2.0M | ||
| Q1 25 | $-2.4M | $-3.5M | ||
| Q4 24 | $-2.2M | $-1.7M | ||
| Q3 24 | $-3.1M | $-2.9M | ||
| Q2 24 | $-3.2M | $-3.5M | ||
| Q1 24 | $-4.2M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | -131.0% | 92.9% | ||
| Q2 25 | -579.4% | 92.5% | ||
| Q1 25 | 59.1% | 92.2% | ||
| Q4 24 | -250.5% | 91.4% | ||
| Q3 24 | -186.1% | 90.8% | ||
| Q2 24 | 79.4% | 90.0% | ||
| Q1 24 | -361.8% | 89.8% |
| Q4 25 | -1990880.1% | 23.5% | ||
| Q3 25 | -90654.1% | 11.2% | ||
| Q2 25 | -99174.8% | -0.1% | ||
| Q1 25 | -2073.3% | -8.9% | ||
| Q4 24 | -23848.9% | 18.6% | ||
| Q3 24 | -55296.7% | 3.6% | ||
| Q2 24 | -3664.6% | -14.3% | ||
| Q1 24 | -73734.7% | -8.3% |
| Q4 25 | -1740028.0% | -5.9% | ||
| Q3 25 | -2146264.3% | -115.5% | ||
| Q2 25 | -77198.4% | -7.8% | ||
| Q1 25 | -2214.6% | -15.1% | ||
| Q4 24 | -24676.9% | -6.5% | ||
| Q3 24 | -79208.9% | -13.2% | ||
| Q2 24 | -4730.1% | -17.4% | ||
| Q1 24 | -86843.2% | -9.5% |
| Q4 25 | — | $-0.32 | ||
| Q3 25 | — | $-3.40 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.41 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.41 | ||
| Q1 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.8M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $47.7M | $5.9M |
| Total Assets | $52.9M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.8M | $16.6M | ||
| Q3 25 | $181.7K | $14.9M | ||
| Q2 25 | $506.1K | $17.0M | ||
| Q1 25 | $3.1M | $20.7M | ||
| Q4 24 | $611.8K | $15.9M | ||
| Q3 24 | $3.1M | $16.3M | ||
| Q2 24 | $5.3M | $6.2M | ||
| Q1 24 | $5.2M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $47.7M | $5.9M | ||
| Q3 25 | $-77.4M | $6.1M | ||
| Q2 25 | $-1.7M | $35.4M | ||
| Q1 25 | $-145.8K | $36.7M | ||
| Q4 24 | $-202.6K | $39.4M | ||
| Q3 24 | $2.0M | $39.8M | ||
| Q2 24 | $4.1M | $41.7M | ||
| Q1 24 | $4.1M | $43.3M |
| Q4 25 | $52.9M | $72.9M | ||
| Q3 25 | $3.1M | $71.1M | ||
| Q2 25 | $3.4M | $98.8M | ||
| Q1 25 | $5.9M | $96.4M | ||
| Q4 24 | $5.0M | $88.1M | ||
| Q3 24 | $7.5M | $88.5M | ||
| Q2 24 | $10.6M | $73.4M | ||
| Q1 24 | $10.6M | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.9M | $3.9M |
| Free Cash FlowOCF − Capex | — | $3.9M |
| FCF MarginFCF / Revenue | — | 14.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.9M | $3.9M | ||
| Q3 25 | $-1.7M | $2.2M | ||
| Q2 25 | $-3.3M | $2.7M | ||
| Q1 25 | $-985.8K | $-2.0M | ||
| Q4 24 | $-2.1M | $932.0K | ||
| Q3 24 | $-2.5M | $2.1M | ||
| Q2 24 | $-3.2M | $-1.4M | ||
| Q1 24 | $-3.4M | $-1.6M |
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $902.7K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | $-2.1M | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | $-3.4M | $-1.7M |
| Q4 25 | — | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | -23429.1% | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | -70379.8% | -9.0% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 4.0% | ||
| Q2 25 | 0.0% | 6.8% | ||
| Q1 25 | 0.0% | 7.4% | ||
| Q4 24 | 73.7% | 0.3% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 62.4% | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGPU
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
